Company Intelligence

Insilico Medicine

Insilico Medicine provides enterprise-grade artificial intelligence solutions, delivering specialized Insilico Medicine Platform technology designed to optimize mission-critical workflows across enterprise software developers and digital transformation teams.

Headquarters
Hong Kong, Hong Kong
Founded
2014
Status
Active
Products
1
Reports
8
Last reviewed
Aug 2026

Overview

What this company is, what it builds, and who it serves.

Insilico Medicine is a Healthcare AI company based in Hong Kong, Hong Kong, founded in 2014.

Clinical-stage generative AI biotechnology company advancing Rentosertib and a broad AI-discovered pipeline.

Verified founder profile on Brel: Alex Zhavoronkov.

What it builds

Insilico Medicine Platform

Why It Matters

Insilico Medicine provides enterprise-grade artificial intelligence solutions, delivering specialized Insilico Medicine Platform technology designed to optimize mission-critical workflows across enterprise software developers and digital transformation teams.

Products

Products and platforms connected to this company.

Founders

People linked to this company in the Brel founder graph.

Ecosystem

How this company connects across the Brel AI intelligence graph.

Company

Insilico Medicine

Industry

Industries served

  • Biotechnology

Capabilities

Insilico's generative chemistry creates novel molecular structures optimized for developability, not just scoring existing libraries. PandaOmics integrates literature, patents, causal networks, and…

Features

Pharma.AI platform spanning PandaOmics target discovery, Chemistry42 generative chemistry, and clinical development tools — plus an internal pipeline of AI-originated drug candidates…

Integrations

  • PandaOmics integrates literature
  • patents
  • causal networks
  • aging hallmarks to rank targets such as TNIK for fibrosis.

Country

Hong Kong

Official Resources

Official and developer links on file for this company.

Latest Developments

Verified developments and timeline notes on file.

  • June 27, 2023: First generative AI-designed drug entered Phase II trials with first patients dosed (Rentosertib program). Latest
  • Company founded 2014 · founded Source
  • Development 2014 · development Source

Frequently Asked Questions

What does Insilico Medicine do?

Insilico Medicine specializes in artificial intelligence, developing Insilico Medicine Platform to support enterprise software developers and digital transformation teams with scalable, production-grade technology.

Where is Insilico Medicine based and when was it founded?

Insilico Medicine is based in Hong Kong and was founded in 2014.

What are the main products offered by Insilico Medicine?

The flagship platform from Insilico Medicine is Insilico Medicine Platform, delivered primarily through b2b saas and enterprise api licensing.

Who are the primary target users of Insilico Medicine?

Insilico Medicine primarily serves enterprise software developers and digital transformation teams seeking reliable artificial intelligence implementations.

Sources & Verification

How this profile is verified and where the information comes from.

Verified
Last reviewed Aug 2026

Primary sources

Request a correction if you represent this company or believe information is inaccurate.